| Autor: |
Ang HX; Genome Institute of Singapore, Agency for Science, Technology & Research, Singapore., Chan SL; Translational Laboratory in Genetic Medicine, Agency for Science, Technology & Research, Singapore., Sani LL; Genome Institute of Singapore, Agency for Science, Technology & Research, Singapore., Quah CB; Genome Institute of Singapore, Agency for Science, Technology & Research, Singapore., Brunham LR; Translational Laboratory in Genetic Medicine, Agency for Science, Technology & Research, Singapore.; Department of Medicine, Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada., Tan BOP; Genome Institute of Singapore, Agency for Science, Technology & Research, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore.; Cancer & Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore.; Division of Cellular & Molecular Research, National Cancer Centre Singapore, Singapore., Winther MD; Genome Institute of Singapore, Agency for Science, Technology & Research, Singapore. |
| Abstrakt: |
While early pharmacogenomic studies have primarily been carried out in Western populations, there has been a notable increase in the number of Asian studies over the past decade. We systematically reviewed all pharmacogenomic studies conducted in Asia published before 2016 to highlight trends and identify research gaps in Asia. We observed that pharmacogenomic research in Asia was dominated by larger developed countries, notably Japan and Korea, and mainly driven by local researchers. Studies were focused on drugs acting on the CNS, chemotherapeutics and anticoagulants. Significantly, several novel pharmacogenomic associations have emerged from Asian studies. These developments are highly encouraging for the strength of regional scientific and clinical community and propound the importance of discovery studies in different populations. |
